Rosetta, Precision Therapeutics Amend Co-marketing Deal Again | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 2012 and revised in October.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.